What is Elucid?
Headquartered in Boston, Elucid operates at the intersection of medical technology and artificial intelligence. The company provides physicians with a sophisticated, cost-effective diagnostic suite designed to optimize treatment pathways for patients suffering from cardiovascular disease. As the first entity to receive FDA clearance and CE marking for non-invasive software capable of quantifying atherosclerotic plaque characteristics—specifically the Lipid Rich Necrotic Core—Elucid occupies a unique market position. Its technology serves as a critical decision-support tool, enabling clinicians to move beyond traditional imaging limitations and embrace data-driven, personalized therapeutic strategies.
How much funding has Elucid raised?
Elucid has raised a total of $45.2M across 3 funding rounds:
Grant
$696K
Series A
$8M
Private Equity
$36.5M
Grant (2014): $696K with participation from National Science Foundation
Series A (2021): $8M led by Checkmate Capital, University of Michigan, Willamette Valley Capital, MedTex Ventures, Angel Physicians Fund, Global Health Impact Fund, BlueStone Venture Partners, and IAG Capital Partners
Private Equity (2025): $36.5M, investors not publicly disclosed
Key Investors in Elucid
Checkmate Capital
A management consulting and investment firm that specializes in creating special situation opportunities across the biotechnology, energy, and waste sectors.
BlueStone Venture Partners
A life sciences venture capital fund dedicated to identifying and supporting innovative companies located outside of traditional investment hubs in the United States.
Angel Physicians Fund
A clinician-led venture capital firm that provides strategic mentorship and clinical expertise to early-stage healthcare technology companies.
What's next for Elucid?
With the infusion of $36.5M, Elucid is well-positioned to accelerate its commercial expansion and deepen its clinical impact. The current lifecycle stage, characterized by major enterprise-level funding, suggests a strategic pivot toward scaling operations and broadening the clinical utility of its AI-driven diagnostic platform. Future initiatives will likely focus on expanding the reach of its FDA-cleared software, fostering new partnerships within the global healthcare ecosystem, and continuing to refine its predictive algorithms to address the evolving complexities of cardiovascular health. By maintaining its commitment to rigorous clinical validation, Elucid is set to solidify its role as an essential component of modern, precision-oriented cardiology.
See full Elucid company page
